Sign In
Buy KHTRF
$5.99
+0.0800 (+1.35%)
At Close: Jun 03, 2026
Knight Therapeutics Inc. (KHTRF) CEO Samira Sakhia on Q3 2021 Results - Earnings Call Transcript
12:14am, Friday, 12'th Nov 2021
Knight Therapeutics Inc. (KHTRF) CEO Samira Sakhia on Q3 2021 Results - Earnings Call Transcript
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
11:08am, Thursday, 23'rd Sep 2021
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related: Incyte's Pemazyre Wi
Knight Therapeutics Inc.'s (KHTRF) CEO Jonathan Ross Goodman on Q2 2021 Results - Earnings Call Transcript
12:33pm, Friday, 13'th Aug 2021
Knight Therapeutics Inc.'s (KHTRF) CEO Jonathan Ross Goodman on Q2 2021 Results - Earnings Call Transcript
Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
07:30am, Friday, 06'th Aug 2021
MONTREAL, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2021 f
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q1 2021 Results - Earnings Call Transcript
01:18pm, Friday, 14'th May 2021
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q1 2021 Results - Earnings Call Transcript
Knight Therapeutics Inc. announces voting results from the Annual Meeting
09:50pm, Thursday, 13'th May 2021
MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin
Knight Therapeutics to Acquire Regional Rights to Exelon®
07:30am, Friday, 23'rd Apr 2021
MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definiti
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call Transcript
03:01pm, Thursday, 25'th Mar 2021
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call Transcript
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q3 2020 Results - Earnings Call Transcript
12:47pm, Friday, 13'th Nov 2020
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q3 2020 Results - Earnings Call Transcript
Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
07:30am, Friday, 06'th Nov 2020
MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2020 fi
